Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical ...

Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments. Received $1 million milestone payment for animal-free recombinant albumin ...

India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform ...

Investor Conference call at 5:00 p.m. ET today. JUPITER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a ...

Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief ...

Dyadic International Inc (NASDAQ:DYAI) reported a significant increase in revenue for Q3 2024, reaching approximately $1,958,000 compared to $397,000 for the same period a year ago. The company ...

Dyadic International DYAI is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release. Analysts are estimating ...